However, a recurrent challenge is the loss of CD19 expression in B-ALL, leading to diminished effectiveness of anti-CD19 CAR-T therapies, despite their standardization in leukemia treatment [17–19]. Here, CD19 is linked to acute lymphoblastic leukemia.